Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 3:9:1011836.
doi: 10.3389/fnut.2022.1011836. eCollection 2022.

FruHis significantly increases the anti-benign prostatic hyperplasia effect of lycopene: A double-blinded randomized controlled clinical trial

Alireza Sadeghi  1 , Ahmad Saedisomeolia  1   2 , Leili Jalili-Baleh  3 , Mehdi Khoobi  4 , Mohammad Soleimani  5 , Ali Mohammad Fakhr Yasseri  6 , Mir Saeed Yekaninejad  7 , Amirreza Farzin  8 , Erfan Amini  8 , Mohammad Reza Nowroozi  8
Affiliations

FruHis significantly increases the anti-benign prostatic hyperplasia effect of lycopene: A double-blinded randomized controlled clinical trial

Alireza Sadeghi et al. Front Nutr. .

Abstract

Background: For decades, lycopene was considered the main compound of tomato protecting benign prostatic hyperplasia (BPH). Recent animal studies suggest that a newly discovered compound "FruHis" boosts lycopene for its action. This study aimed to determine whether FruHis enhances the action of lycopene to modify the laboratory parameters and clinical outcomes of patients with BPH.

Materials and methods: Current study was conducted on 52 BPH patients, who were randomly assigned into four groups of treatments: lycopene plus FruHis (n = 11, 25 mg/day lycopene and 10 mg/day FruHis), lycopene (n = 12, 25 mg/day lycopene), FruHis (n = 12, 10 mg/day FruHis), and placebo (n = 13). Patients received these supplements for 8 weeks.

Results: FruHis intake strengthened the reducing effects of lycopene on insulin-like growth factor-1 (IGF-1) (-54.47 ± 28.36 ng/mL in the lycopene + FruHis group vs. -30.24 ± 46.69 ng/mL in the lycopene group), total prostate-specific antigen (TPSA) (-1.49 ± 4.78 ng/mL in the lycopene + FruHis group vs. -0.64 ± 2.02 ng/mL in the lycopene group), and symptom score (-4.45 ± 4.03 in the lycopene + FruHis group vs. -1.66 ± 5.41 in the lycopene group) in BPH patients. Such findings were also seen for body mass index (BMI) and waist circumference (WC). However, except for IGF-1, these reductions were not statistically significant compared with the placebo, and the intakes of lycopene and FruHis alone, however, were clinically important. Such effects of lycopene and FruHis were not seen for free PSA (FPSA) and FPSA/TPSA ratio.

Conclusion: Despite the non-significant effects of lycopene and FruHis, it seems that FruHis intake strengthens the beneficial effects of lycopene on IGF-1, TPSA, and symptom scores among BPH patients.

Clinical trial registration: [www.irct.ir], identifier [IRCT20190522043669N1].

Keywords: FruHis; benign prostatic hyperplasia; lycopene; prostate specific antigen; tomato.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
The flowchart of the current study.
FIGURE 2
FIGURE 2
The effects of lycopene and FruHis supplementation, combined and alone, on TPSA (A), IGF-1 (B), symptom score (C), and QoL improvement (D) among patients with BPH. QoL improvement was considered as changing the scores of 4–6 to 0–3 (based on QoL question in IPSS) throughout the trial. IPSS, international prostate symptom score; QoL, quality of life; TPSA, total prostate-specific antigen; IGF, insulin-like growth factor; BPH, benign prostatic hyperplasia.
See this image and copyright information in PMC

References

    1. Zeng XT, Jin YH, Liu TZ, Chen FM, Ding DG, Fu M, et al. Clinical practice guideline for transurethral plasmakinetic resection of prostate for benign prostatic hyperplasia (2021 Edition). Mil Med Res. (2022) 9:14. 10.1186/s40779-022-00371-6 - DOI - PMC - PubMed
    1. Chughtai B, Forde JC, Thomas DD, Laor L, Hossack T, Woo HH, et al. Benign prostatic hyperplasia. Nat Rev Dis Primers. (2016) 2:16031. - PubMed
    1. Devlin CM, Simms MS, Maitland NJ. Benign prostatic hyperplasia – what do we know? BJU Int. (2021) 127:389–99. - PubMed
    1. Tong Y, Xie K, Li S. Self-care and quality of life in elderly Chinese patients with benign prostatic hyperplasia. Nurs Sci Q. (2020) 33:79–84. 10.1177/0894318419883417 - DOI - PubMed
    1. Tacklind J, Fink HA, Macdonald R, Rutks I, Wilt TJ. Finasteride for benign prostatic hyperplasia. Cochrane Database Syst Rev. (2010) 2010:Cd006015. - PMC - PubMed